Invion Stock

Invion Debt / Assets

Debt-to-Assets Ratio of Invion (IVX.AX) as of Sep 4, 2026.

Debt / Assets

0.00

Last updated:

Debt-to-Assets Ratio of Invion is 2026 0.00 . Debt-to-Assets Ratio of Invion was 2025 0.00 . It decreases by % lower compared to the previous year.

The Invion Debt / Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt / Assets
Date
Debt / Assets
Jan 1, 2016
0.10 AUD
Jan 1, 2017
0.22 AUD
Jan 1, 2018
0.00 AUD
Jan 1, 2019
0.00 AUD
Jan 1, 2020
0.00 AUD
Jan 1, 2021
0.00 AUD
Jan 1, 2022
0.00 AUD
The Invion Debt / Assets history
YEARDebt / AssetsYoY
0.00
0.00
0.00
0.00-100.00%
0.00-99.09%
0.22+115.97%
0.10
Access this data via the Eulerpool API

Invion Stock analysis

What does Invion do? Invion Ltd is an Australian company specializing in the development of treatment solutions for respiratory and inflammatory diseases. The company was originally founded in 2000 and is headquartered in Perth, Western Australia. It began as a company called CBio that focused on developing technology to prevent blood clot formation. In 2004, it was renamed Invion and shifted its focus to developing treatment solutions for respiratory and inflammatory diseases. Invion has acquired several pharmaceutical companies and has developed an innovative pipeline of products. The company is positioned as a biopharmaceutical company specializing in the discovery and development of treatments based on immunological research for the prevention, diagnosis, and treatment of severe respiratory and inflammatory diseases. It utilizes a combination of proprietary platform technology and internal expertise and collaborates with small and mid-sized pharmaceutical companies. Invion is divided into three main business divisions: antiviral treatment, immunomodulation, and diagnostics. In terms of products, Invion has several in development stages, including INV102 for severe asthma, INV103 for Covid-19, INV104 for lung inflammation, INV027 for COPD, and INV043 for allergic asthma. Overall, Invion aims to improve patient care and diagnosis in the respiratory and inflammatory disease space through innovative technologies. Invion is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Invion stock

On Eulerpool you can find the complete historical development of Debt-to-Assets Ratio Invion since 2006 – with annual values, charts, and detailed analysis.

The Debt-to-Assets ratio measures what percentage of a company's assets are financed through debt. Higher ratios indicate greater financial risk.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Debt-to-Assets Ratio's Invion with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Invion

All Key Metrics — Invion